A New Category on the Steatotic Liver Disease Spectrum
In a comprehensive review published in eGastroenterology , Professor Gao from the NIAAA/NIH and colleagues introduce and critically examine metabolic dysfunction and alcohol-associated liver disease (MetALD), a newly defined category that captures patients with hepatic steatosis who have both metabolic risk factors and moderate alcohol consumption.
MetALD represents a disease between metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-associated liver disease (ALD). According to current consensus criteria, MetALD is diagnosed in individuals with at least one cardiometabolic risk factor who consume: 140–350 g/week (women); 210–420 g/week (men).
This nomenclature acknowledges that metabolic dysfunction and alcohol exposure often coexist; and, more importantly, act synergistically to accelerate liver injury.
Diagnosis: Beyond Self-Reported Alcohol Intake
(1) Structured Assessment and Biomarkers
Accurate phenotyping is central to MetALD diagnosis. The review emphasises: (i) Confirmation of hepatic steatosis (imaging or histology); (ii) Documentation of metabolic dysfunction (obesity, T2DM, dyslipidaemia, hypertension); (iii) Rigorous quantification of alcohol intake using structured tools such as Timeline Followback and AUDIT. However, self-reported alcohol use is frequently underestimated. To reduce misclassification, the authors highlight phosphatidylethanol (PEth) as a sensitive biomarker of moderate-to-heavy drinking, detectable for 2–4 weeks. PEth testing can reclassify patients previously labelled as MASLD into MetALD or ALD.
(2) Non-Invasive Fibrosis Assessment
Given fibrosis as the major determinant of outcomes, non-invasive tools such as FIB-4 and transient elastography are recommended for staging and longitudinal monitoring. A key message: patients may migrate between MASLD, MetALD and ALD over time depending on drinking patterns, making dynamic reassessment essential.
Clinical Management: Dual-Target Strategy
MetALD management requires simultaneous control of metabolic risk factors and alcohol use.
(1) Lifestyle Interventions: (i) ≥5–7% weight loss improves steatosis; (ii) ≥10% weight loss may resolve steatohepatitis and regress fibrosis; (iii) Mediterranean diet and ≥150 minutes/week moderate exercise are advised. Alcohol moderation, or ideally abstinence, remains foundational.
(2) Pharmacological Therapies
The review discusses emerging therapeutic intersections: (i) Resmetirom (thyroid hormone receptor β agonist) shows similar benefit in MASLD and MetALD subsets; (ii) GLP-1 receptor agonists (e.g., semaglutide) improve steatosis and may reduce alcohol intake, potentially addressing both drivers of disease. For alcohol use disorder (AUD), FDA-approved agents include acamprosate and naltrexone, with growing interest in GLP-1–based approaches. A major unmet need remains: dedicated MetALD trials rather than extrapolation from MASLD or ALD cohorts.
Pathogenesis: Synergistic Injury at Multiple Axes
The authors underscore that the interaction between metabolic dysfunction and alcohol is not additive but synergistic.
(1) Hepatocyte Injury and Inflammation
Combined high-fat diet and alcohol exposure promote: Lipotoxicity; Oxidative stress; ER stress; CXCL1-mediated neutrophil infiltration; NLRP3 inflammasome activation; Neutrophil extracellular traps (NETs) and macrophage activation amplify fibrogenesis.
(2) Liver Fibrosis
Hepatic stellate cell (HSC) activation remains central. Emerging single-cell and spatial transcriptomic data reveal functional HSC subpopulations and syncytial signalling networks, offering new mechanistic insights. Importantly, fibrosis regression is possible if pathogenic stimuli are removed, but sustained behavioural modification is challenging in MetALD.
(3) Gut–Liver Crosstalk: A Central Amplifier
The review highlights disruption of the gut–liver axis as a core mechanism: (i) Alcohol and metabolic dysfunction drive intestinal dysbiosis; (ii) Acetaldehyde impairs tight junctions; (iii) Bacterial products (e.g., LPS) translocate into portal circulation; (iv) Intestinal immune depletion (CD8+ T cells, macrophages) worsens barrier integrity. These processes intensify hepatic inflammation and fibrogenesis.
(4) Adipose–Liver Axis: The "Second Hit"
Inflamed, insulin-resistant adipose tissue increases free fatty acid flux to the liver. Alcohol further elevates NADH/NAD+ ratio; suppresses β-oxidation; and induces CYP2E1-mediated oxidative stress. Adipocyte death and S100A8+ macrophage signalling promote hepatic steatosis and lipotoxicity. In obesity, alcohol acts as a "second hit," accelerating progression from steatosis to steatohepatitis and fibrosis.
Key Research Priorities
The review outlines urgent challenges: (i) Validated PEth thresholds across populations; (ii) Genetic susceptibility profiling (e.g., PNPLA3, TM6SF2, ADH1B, ALDH2); (iii) Integration of polygenic risk scores; (iv) Dedicated MetALD clinical trials; (v) Multidisciplinary AUD–hepatology care models.
Conclusion
MetALD reflects the real-world convergence of metabolic dysfunction and alcohol exposure. By formally defining this overlapping phenotype, the field moves toward more precise risk stratification and personalised therapy. However, as Gao and colleagues emphasise, the term's conceptual clarity masks biological and clinical complexity. Progress will depend on improved alcohol quantification, refined mechanistic models and integrated metabolic–addiction care frameworks. MetALD is not merely a diagnostic label, instead, it is a call to rethink how metabolic and behavioural risk intersect in chronic liver disease.
See the article:
Gao B, Arab JP, Liangpunsakul S, et al. Metabolic dysfunction and alcohol-associated liver disease (MetALD). eGastroenterology 2025;3:e100319. doi:10.1136/ egastro-2025-100319
About eGastroenterology
eGastroenterology, a BMJ journal partnered with Gut and launched by leading scientists in gastroenterology and hepatology, has been indexed in the Web of Science Core Collection (ESCI), PubMed, DOAJ, Scopus, CAS, ROAD, and many other major international databases within just two years of its launch. The journal is expecting to receive its first Impact Factor in June 2026.
